ARTICLE BY LOUIS

  • Safe At Home With Generics
    7/13/2022

    “I have not wanted to go to India or China for most of my API needs, and to the extent possible I do not want to go there for formulations either,” is part of a surprising sentiment from a long-tenured generics outsourcing professional.  

  • The Hardest Job In All BioPharma: The CTO
    6/1/2022

    CTO roles have expanded, deepened, and pressurized – particularly at drug sponsors reliant on outsourcing development and manufacturing capabilities. Now CTOs are actively seeking ways to improve their leadership skills so they can better handle the transforming environment.

  • We’ve Moved Forward
    3/1/2022

    In addition to our annual CMO Leadership awards, what you’ll read in these pages is the importance of continuing to advance the knowledge, best practices, and strategies of outsourcing we’ve been covering now for nearly a decade in this issue.

  • Outsourcing From A To ZZ Biotech
    3/1/2022

    Kent Pryor, CEO of ZZ Biotech, explains how he’s approached his single-handed “CEO As Outsourcer” role and provides advice to professionals of all positions in any biopharma organization.

  • Defending Your Supply Chains From “Foreign Suppliers”
    1/13/2022

    In “defense” of the integrity of your (offshore and onshore) drug development and manufacturing outsourcing, and during this year 3 CE (Covid Era): Considering suppliers as separate and somewhat removed entities – putting them at a distance – might be what it takes to subsequently bring you even closer to reliable partnerships. 

  • These Professionals Are Creating Our Outsourcing Future
    12/1/2021

    While asking executives their views on the future of outsourcing drug development and manufacturing, I arrived at an epiphany of sorts: They are the future of biopharma outsourcing.

  • Should You Build Where You Buy? A Rarely Discussed Model For Biopharma
    9/23/2021

    You are an emerging biopharma outsourcing to a trusted CDMO that has selected its location wisely – an important factor in your selecting it. Now you’ve determined to establish some of your own development or manufacturing facilities. Would it be beneficial to build close to your CDMO?

  • Not Particularly For A Pandemic, But The Supply Chain Was Ready
    8/18/2021

    A discussion on lessons learned from the pandemic featured Remo Colarusso, Vice President, Janssen Supply Chain, Johnson & Johnson, and Ken Kent, Senior Vice President, Chemical Development and Manufacturing Operations, Gilead Sciences, at a recent DCAT Virtual Week event.

  • Leaders Have An Appetite For Adaptability When Outsourcing
    6/23/2021

    In part one - "Five Maxims For Outsourcing Success" - we tackled Lisa Wyman's first three of five tenets to better outsource by. Here we explore her belief that leveraging capabilities and capacities of CDMOs is predicated on an appetite for adaptability and flexibility, and that is exhibited as a quality of leadership.

  • An All-Canada COVID-19 Vaccine Solution
    6/1/2021

    The story of how Providence Therapeutics, a Calgary, Ontario-based, emerging mRNA biopharma, came to achieve such notoriety is an interesting one that includes a pivot from its core therapeutic focus, the hiring of an American as company president, and the creation of a CDMO.

louis-g-photo-edited

Louis Garguilo



Louis Garguilo is chief editor and conference chair for Outsourced Pharma, and a contributing editor to Life Science Leader magazine. He studied public relations and journalism at Syracuse University (and holds a Master’s in English), and has 30+ years of international experience in business communications and development positions. Louis spent a decade at a global pharmaceutical contract research, development and manufacturing organization; served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; was chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and business communications consultant, including for the Osaka Medical Center for Cancer and Cardiovascular Diseases.